Current Issue

Year 2019

Volume: 6 , Issue: 3

Print ISSN:-2394-2746

Online ISSN:-2394-2754

Member of

Indian Journal of Obstetrics and Gynecology Research

Role of ormeloxifene in AUB/HMB

Full Text PDF Share on Facebook Share on Twitter

Author Details: Uma Pandey

Volume : 5

Issue : 3

Online ISSN : 2394-2754

Print ISSN : 2394-2746

Article First Page : 392

Article End Page : 394


Introduction: Heavy menstrual blood loss is defined as >80 ml of blood loss during menstruation. Abnormal uterine bleeding is abnormal menstruation as regards volume, regularity, frequency and duration of bleeding.
Materials and Methods: A total of 100 patients of age group 25-45 years were included in this study. Patients were thoroughly investigated before inclusion. Exclusion criteria were any women with fibroid, adenomyosis, endometrial hyperplasia, breast cancer and coagulopathy. Patients were thoroughly investigated before therapy. Ormeloxifene was administered orally 60mg twice a week for 3 months followed by 60mg once a week for a month.
Results: Amenorrhoea was 33% at 3 months follow up which is increased further to 42% at 4 months follow up. Similarly 44% women had scanty flow at the end of 4 months treatment. Comparison of clinical characteristics shows reduction in duration of menstrual blood loss and rise in haemoglobin (from 7.2 to 9 gm/dl, which is along with oral iron supplementation). Passage of blood also reduced considerably, although 7 (7.4%) women did not show good response.
Conclusion: The study concluded that ormeloxifene is a good option as it is cheap, has twice weekly schedule, few side effects and efficacious in reducing the menstrual blood loss.

Keywords: Heavy menstrual blood loss, Abnormal uterine bleeding, Fibroid, Adenomyosis, Ormeloxifene.

Doi :-